Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Free Cash Flow (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Free Cash Flow for 12 consecutive years, with -$16.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Free Cash Flow fell 41.87% year-over-year to -$16.4 million, compared with a TTM value of -$52.2 million through Sep 2025, down 42.05%, and an annual FY2024 reading of -$49.1 million, down 59.08% over the prior year.
  • Free Cash Flow was -$16.4 million for Q3 2025 at Avalo Therapeutics, down from -$11.4 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $5.6 million in Q3 2022 and bottomed at -$19.2 million in Q2 2021.
  • Average Free Cash Flow over 5 years is -$11.3 million, with a median of -$11.5 million recorded in 2024.
  • The sharpest move saw Free Cash Flow surged 134.4% in 2022, then plummeted 443.89% in 2024.
  • Year by year, Free Cash Flow stood at -$17.1 million in 2021, then surged by 77.53% to -$3.8 million in 2022, then grew by 28.06% to -$2.8 million in 2023, then tumbled by 443.89% to -$15.0 million in 2024, then decreased by 8.7% to -$16.4 million in 2025.
  • Business Quant data shows Free Cash Flow for AVTX at -$16.4 million in Q3 2025, -$11.4 million in Q2 2025, and -$9.5 million in Q1 2025.